Joseph P. Costantino
#164,508
Most Influential Person Now
Joseph P. Costantino's AcademicInfluence.com Rankings
Joseph P. Costantinomathematics Degrees
Mathematics
#7469
World Rank
#10151
Historical Rank
Statistics
#864
World Rank
#956
Historical Rank
Joseph P. Costantinophilosophy Degrees
Philosophy
#9623
World Rank
#13211
Historical Rank
Logic
#6590
World Rank
#8121
Historical Rank
Download Badge
Mathematics Philosophy
Joseph P. Costantino's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Biostatistics University of California, Berkeley
Why Is Joseph P. Costantino Influential?
(Suggest an Edit or Addition)Joseph P. Costantino's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. (1999) (5389)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. (2006) (2385)
- Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (1594)
- A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. (1989) (1427)
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. (2010) (1366)
- Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. (2005) (1251)
- Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. (2007) (909)
- Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. (1996) (884)
- Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. (1993) (821)
- Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. (2001) (751)
- Validation studies for models projecting the risk of invasive and total breast cancer incidence. (1999) (704)
- Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. (2007) (684)
- Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. (2011) (680)
- Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. (1999) (666)
- Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. (1994) (662)
- Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. (1998) (637)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010) (594)
- Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. (2010) (543)
- Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. (1999) (444)
- Bevacizumab added to neoadjuvant chemotherapy for breast cancer. (2012) (432)
- Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection (2010) (424)
- Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. (2009) (400)
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data (2013) (398)
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. (2021) (398)
- A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure. (2000) (353)
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. (2013) (327)
- Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. (2008) (310)
- Projecting individualized absolute invasive breast cancer risk in African American women. (2007) (306)
- Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. (2010) (305)
- Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B‐17. Intraductal carcinoma (ductal carcinoma in situ) (1995) (291)
- Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. (1990) (283)
- Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. (2004) (248)
- Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (247)
- Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial (2019) (230)
- Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and (1996) (226)
- Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. (2007) (226)
- Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. (2012) (200)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Association of tamoxifen and uterine sarcoma. (2002) (196)
- Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20 (2011) (191)
- Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. (2011) (170)
- Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. (2012) (166)
- Coronary heart disease mortality and adjuvant tamoxifen therapy. (1997) (160)
- Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. (2011) (156)
- Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. (2010) (154)
- NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. (2019) (141)
- Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) (137)
- Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. (2001) (134)
- Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. (2015) (131)
- Occupationally Related Cancer Risk Among Coke Oven Workers: 30 Years of Follow-Up (1995) (131)
- Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. (2011) (129)
- Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. (2011) (122)
- Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. (2013) (121)
- Validating and improving models for projecting the absolute risk of breast cancer. (2001) (121)
- Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. (2009) (119)
- Long-term tamoxifen citrate use and potential ocular toxicity. (1998) (114)
- Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. (2011) (113)
- Flow cytometric DNA analysis of Neuroblastoma and Ganglioneuroma. A 10‐year retrospective study (1988) (112)
- Multivariate predictors of failed prehospital endotracheal intubation. (2003) (112)
- Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant Trials (2010) (109)
- Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. (2015) (107)
- Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B‐17: Intraductal carcinoma (ductal carcinoma in situ) (1995) (107)
- Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. (2001) (105)
- Accuracy of end-tidal and transcutaneous PCO2 monitoring during sleep. (1994) (104)
- Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial (2008) (104)
- Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials (2012) (103)
- 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy (2017) (103)
- Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer (2005) (102)
- Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. (2013) (101)
- OT2-06-02: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413. (2011) (100)
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
- Adequacy of prescribing positive airway pressure therapy by mask for sleep apnea on the basis of a partial-night trial. (1993) (99)
- Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. (2015) (97)
- Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. (2006) (97)
- Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. (2011) (91)
- Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. (2005) (89)
- The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. (2002) (88)
- Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. (2003) (82)
- Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial (2017) (81)
- Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H) (2006) (81)
- Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer (2013) (79)
- Prognosis among African‐American women and white women with lymph node negative breast carcinoma (1997) (77)
- Diagnosis of sleep-disordered breathing by half-night polysomnography. (1991) (77)
- Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 (2007) (75)
- Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. (2007) (74)
- Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials (2008) (72)
- Lower-category benign breast disease and the risk of invasive breast cancer. (2004) (71)
- Serum level changes after administration of a pharmacologic dose of beta-carotene. (1988) (71)
- Nonparametric Inference on Median Residual Life Function (2008) (70)
- Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). (2006) (69)
- Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial (2003) (67)
- Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) (66)
- Split-night studies for the diagnosis and treatment of sleep-disordered breathing. (1996) (65)
- Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 (2013) (65)
- Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial (2011) (65)
- Evidence of an altered pattern of breathing during exercise in recipients of heart-lung transplants. (1988) (64)
- Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. (2013) (63)
- Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. (2010) (60)
- Tamoxifen and Cardiac Risk Factors in Healthy Women: Suggestion of an Anti-inflammatory Effect (2001) (60)
- 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1 (2012) (59)
- Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women (2008) (59)
- 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer (2018) (58)
- Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. (2006) (55)
- Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials (2011) (55)
- The impact of split-night polysomnography for diagnosis and positive pressure therapy titration on treatment acceptance and adherence in sleep apnea/hypopnea. (2000) (54)
- Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. (2012) (52)
- Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. (2009) (50)
- S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen- receptor-positive breast cancer (2004) (50)
- The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. (2004) (47)
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial (2006) (46)
- National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. (2003) (46)
- 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. (2010) (45)
- Tamoxifen and Cardiac Risk Factors in Healthy Women Suggestion of an Anti-inflammatory Effect (2001) (44)
- Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer (2019) (42)
- Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer (2004) (42)
- Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies (2012) (41)
- Using alternative comparison populations to assess occupation-related mortality risk. Results for the high nickel alloys workers cohort. (1998) (39)
- Breast cancer risk factors and mammographic breast density in women over age 70 (2006) (39)
- Chromosomal aberrations and sister-chromatid exchanges in lymphocytes from coke oven workers. (1988) (38)
- Inductance plethysmography measurement of CPAP-induced changes in end-expiratory lung volume. (1990) (38)
- Cigarette Smoking, Physical Activity, and Alcohol Consumption as Predictors of Cancer Incidence among Women at High Risk of Breast Cancer in the NSABP P-1 Trial (2014) (36)
- Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38 (2015) (36)
- NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. (2009) (35)
- Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS? (2007) (34)
- The use of tamoxifen and raloxifene for the prevention of breast cancer. (2009) (32)
- 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology (2018) (32)
- Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28. (2012) (30)
- Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. (2016) (29)
- Multistage modeling of lung cancer mortality among arsenic-exposed copper-smelter workers. (1989) (29)
- Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0) (2007) (29)
- Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer. (2019) (29)
- OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). (2015) (28)
- Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). (2011) (27)
- Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary. (2009) (27)
- Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23 (2005) (27)
- Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. (2010) (26)
- Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). (2014) (26)
- S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. (2011) (25)
- The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (2011) (25)
- A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. (2008) (25)
- Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial bre (2010) (25)
- Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR) (2012) (25)
- Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. (1998) (24)
- Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. (2007) (24)
- The impact of systemic therapy following ductal carcinoma in situ. (2010) (24)
- Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial (2013) (23)
- A multistage approach to the cohort analysis of lifetime lung cancer risk among steelworkers exposed to coke oven emissions. (1988) (23)
- Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28 (2012) (23)
- Cognitive Factors Associated with Adherence to Oral Antiestrogen Therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Study (2013) (22)
- Is boost therapy necessary in the treatment of DCIS (2008) (21)
- The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. (2002) (21)
- Breathing during wakefulness and sleep after human heart-lung transplantation. (1989) (20)
- The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. (2006) (20)
- Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. (2016) (19)
- Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. (2015) (19)
- Optical charaterization of black appliques (1996) (18)
- Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. (2006) (17)
- Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. (2010) (17)
- Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. (2010) (17)
- Prediction of accrual closure date in multi‐center clinical trials with discrete‐time Poisson process models (2012) (16)
- Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) → docetaxel (T) arm of NSABP B-30: Preliminary results (2005) (16)
- The Landmark Surgical Trials of the National Surgical Adjuvant Breast and Bowel Project (2006) (15)
- Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. (2008) (15)
- The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. (2008) (14)
- Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer (2018) (14)
- NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (14)
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2018) (13)
- The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (2011) (13)
- Response—blunting the counterpoint (1995) (12)
- Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer (2015) (12)
- Abstract S2-05: 10-yr follow-up results of occult detected sentinel node disease: NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients (2013) (12)
- Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. (2010) (12)
- NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC->paclitaxel (P) plus gemcitabine (G) with DD AC->P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (11)
- Issues and findings in the evaluation of occupational risk among women high nickel alloys workers. (1999) (11)
- Inference of Tamoxifen's Effects on Prevention of Breast Cancer From a Randomized Controlled Trial (2007) (11)
- Sam Wieand, PhD (2006) (11)
- The effect of obliterative bronchiolitis on breathing pattern during exercise in recipients of heart-lung transplants. (1991) (10)
- Recent developments in the multistage modeling of cohort data for carcinogenic risk assessment. (1991) (10)
- Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40 (2015) (10)
- IS TAMOXIFEN A RISK FACTOR FOR RETINAL VASO-OCCLUSIVE DISEASE? (2005) (10)
- Polysomnography early after uvulopalatopharyngoplasty as a predictor of late postoperative results. (1990) (10)
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF 423 Regulation of BRCA 1 Expression : Individualized Breast Cancer Prevention (2013) (9)
- Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24 (2007) (9)
- Methodological Issues in the Analysis of Quality of Life Data in Clinical Trials: Illustrations from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (2002) (9)
- Application of Smoothing Methods to Evaluate Treatment-Prognostic Factor Interactions in Breast Cancer Data (2006) (9)
- The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40 (2017) (8)
- Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials. (2014) (8)
- RESPONSE: Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (2006) (7)
- Prescription of positive airway pressure for sleep apnea on the basis of a partial-night trial. (1993) (7)
- Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. (2019) (7)
- The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 Breast Cancer Prevention Study. (2006) (7)
- Erratum to: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1 (2012) (7)
- Challenges in Monitoring the Breast Cancer Prevention Trial (2006) (6)
- NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer. (2013) (6)
- Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. (2015) (6)
- Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT). (2011) (6)
- Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view. (2001) (6)
- Breast cancer trials on trial: a case of conflicting ethical interests. (1995) (5)
- NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. (2009) (5)
- Electronic monitoring of participant adherence in the NSABP breast cancer prevention trial (BSPT) (1998) (5)
- PD07-08: The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40. (2011) (5)
- Time-dependent patterns of recurrence after early stage breast cancer: Preliminary observations and methodological issues (2007) (5)
- Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. (2002) (5)
- Abstract S6-03: The prognosis of small HER2+ breast cancers: A meta-analysis of the randomized trastuzumab trials (2013) (5)
- Mucocele-like Lesions and Mucinous Carcinoma of the Breast (1994) (5)
- NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC). (2018) (4)
- Landmark proportional subdistribution hazards models for dynamic prediction of cumulative incidence functions (2019) (4)
- Design and current status of the NSABP breast cancer prevention trial. (1996) (4)
- Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR) (2008) (4)
- Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29 (2015) (4)
- Abstract P6-07-01: Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28 (2012) (4)
- Robust prediction of the cumulative incidence function under non‐proportional subdistribution hazards (2016) (4)
- 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer (2018) (3)
- Conclusions: Considerations regarding SERMs. (2006) (3)
- Abstract OT2-04-08: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2020) (3)
- Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab (2018) (3)
- Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration (2010) (3)
- Authors’ reply to the letter to the editor on the paper ‘Prediction of accrual closure date in multi‐center clinical trials with discrete‐time Poisson process models’ (2012) (3)
- Abstract S4-9: Comparing the Prediction of Chemotherapy Benefit in Patients with Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and a New Measure That Integrates Clinical and Pathologic Factors with the Recurrence Score (2010) (3)
- Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. (2016) (3)
- Benefit/Risk Assessment of SERM Therapy (2001) (3)
- Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings. (2001) (3)
- Abstract P3-10-04: The fully validated NSABP/NRG 8-gene signature which predicted the degree of benefit in the adjuvant setting (B-31 and NCCTG N9831) associates with pCR in the neoadjuvant setting in NSABP clinical trial FB-7 (2019) (2)
- The case for underground diesels (1984) (2)
- Abstract PD2-1: Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38 (2013) (2)
- Abstract S6-04: Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy (2016) (2)
- Primary results , NSABP B-35 / NRG Oncology : A clinical trial of anastrozole vs tamoxifen in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy A randomized clinical trial (2016) (2)
- Predictive Factors for Positive Non-Sentinel Nodes Following a Positive Sentinel Node Biopsy: NSABP B-32. (2009) (2)
- Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. (2012) (2)
- 'Health costs of air pollution' challenged. (1980) (2)
- P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33 (2007) (2)
- Stat Bite : Breast Cancer Risk in Prevention Trial Participants (1994) (1)
- Correlation of levels of Akt phosphorylation at Ser473 with benefit from paclitaxel chemotherapy in NSABP B-28 patients with node-positive breast cancer. (2016) (1)
- Reminiscence of Samuel H. Wieand: the NSABP Years (2008) (1)
- Re: Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress? (2000) (1)
- Breast cancer trials on trial: A case of conflicting ethical interests (1995) (1)
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2019) (1)
- Computations of adjusted rates and lifetime risks from occupational cohort data: a program package using FORTRAN and GLIM. (1991) (1)
- Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2019) (1)
- Evaluation of the effect of coal cleaning on fugitive elements. Final report: Phase II. Part III. State-of-the-art: fate of trace elements in coal during mining, preparation, and utilization. [1076 references] (1981) (1)
- Rethinking the role of nodal status in TNM staging of node-positive breast cancer (2007) (1)
- Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52 (2019) (1)
- Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial. (2011) (1)
- Vasomotor symptoms, BMI, and adherence to tamoxifen in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1). (2015) (1)
- The Study of Tamoxifen and Raloxifene (STAR): Change in patient-reported outcomes (PROs) after the end of treatment (2007) (1)
- Cigarette smoking, fitness, and obesity as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention Trial (BCPT). (2010) (1)
- Abstract 2711: Graphical method to predict drug response using genomic biomarkers with nonlinear interaction effect (2012) (0)
- The Use of Tramoxifen and Roloxifene for the Prevention of Breast Cancer (2009) (0)
- Accuracy ofEnd-Tidal and Transcutaneous Pco2Monitoring During Sleep* (2015) (0)
- 25-hydroxy vitamin D (VitD) and associated variables as predictors of breast cancer (BC) risk and tamoxifen benefit in NSABP-P1. (2011) (0)
- Tamoxifen and Retinal Vaso–Occlusive Disease (2004) (0)
- P3-13-01: Boost Radiation Therapy Not of Value in Reducing IBTR of Invasive or Noninvasive Breast Cancers for Patients with DCIS: Results from the NSABP B-24 Trial. (2011) (0)
- Tamoxifen treatment for breast cancer was associated with an increased risk of endometrial cancer (1999) (0)
- Response:Re: Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women (2008) (0)
- Abstract P5-21-01: Effect of adjuvant systemic therapy in reducing rates of loco-regional recurrence in early-stage breast cancer: Results from nine NSABP randomized phase III trials (2015) (0)
- Original Article Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial (2010) (0)
- EDITORIALS Validating and Improving Models for Projecting the Absolute Risk of Breast Cancer (2001) (0)
- Response to Arnold (1994) (0)
- 8. Benefit/Risk Assessment in Prevention Trials (2014) (0)
- 57 Risk communication strategies during an ongoing clinical trial: Protecting participant safety without causing unnecessary panic, the breast cancer prevention trial (BCPT) experience (1997) (0)
- 107 Global monitoring of prevention trials: the breast cancer prevention trial (bcpt) experience (1997) (0)
- Demographic characteristics and quality of life factors among the participants of the breast cancer prevention trial (1998) (0)
- 1503O Clinical and scientific impact of National Cancer Institute: Sponsored clinical trial network group treatment trials (2021) (0)
- Comparison of self-reported outcomes with arm functional measurements in early breast cancer patients undergoing nodal biopsy in NSABP Protocol B-32 (2005) (0)
- Determinants of participation in the Study of Tamoxifen and Raloxifene (STAR): Experience of a minority-based community oncology program (2005) (0)
- Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer (2011) (0)
- Correlation of serum sex hormone levels with the Gail model risk of breast cancer in postmenopausal women (2008) (0)
- Benefit/Risk Assessment in Prevention Trials (2005) (0)
- Health effects of respirable coal mine dust: coal workers' pneumoconiosis (1981) (0)
- Abstract CT129: Association of the FCGR2A and FCGR3A genotypes with trastuzumab benefit in NSABP B-31 (2015) (0)
- Chemotherapy induced amenorrhea as an indicator of better survival in early breast cancer (2010) (0)
- Patient-reported outcomes and behavioral risk factors as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention P-1 trial. (2014) (0)
- Use of 5- (cid:1) -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/ American Urological Association 2008 Clinical Practice Guideline (2009) (0)
- Should log odds of positive lymph node be incorporated into AJCC TNM breast cancer staging system (2008) (0)
- Session 6 Primary prevention of breast cancer II: Update of chemoprevention with tamoxifen, raloxifen and aromatase-inhibitors (2004) (0)
- Monitoring multiple endpoints in prevention trials. (2006) (0)
- Comment on: Tamoxifen for the prevention of breast cancer : Current status of the national surgical adjuvant breast and bowel project P-1 study. Authors' reply (2006) (0)
- Abstract 4727: Breast cancer prevention and selective estrogen response modulators (SERMs): Pharmacogenomics and differential estrogen and SERM regulation of BRCA1 and BRCA2 expression (2011) (0)
- Statistical concepts and biomedical research. (1996) (0)
- Conclusions (2001) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Joseph P. Costantino?
Joseph P. Costantino is affiliated with the following schools:
